cancerfunds

102 results found.

Top Stocks matching your search for "cancer funds"

Click Learn More to know about Stock Advisor's top picks. We've 3x'd the S&P 500 over the last 20 years.

02/0902/1402/1702/2302/2803/0303/0803/1303/1603/21
TGTX

TG Therapeutics Inc

-19.05%

$18.43 - $14.92

Feb 7th 2023 - Mar 21st 2023

Positive Reviews Happy Facepositive
Negative Reviews Sad Facenegative

Mar, 21, 2023

$TGTX MOST CONVENIENT- 50% faster infusion SAFE... See more

Mar, 13, 2023

INFUSION TIME 3.NO BREAST CANCER ISSUES 4.

02/0902/1402/1702/2302/2803/0303/0803/1303/1603/21
SLS

SELLAS Life Sciences Group Inc

-63.99%

$3.61 - $1.30

Feb 7th 2023 - Mar 21st 2023

Positive Reviews Happy Facepositive
Negative Reviews Sad Facenegative

Mar, 20, 2023

These patients experienced about 35% longer surviv... See more

Mar, 20, 2023

* Best Available Therapy offers 6-8 months of Over... See more

02/0902/1402/1702/2302/2803/0303/0803/1303/1603/21
COSM

Cosmos Holdings Inc

-39.30%

$5.00 - $3.04

Feb 7th 2023 - Mar 21st 2023

Positive Reviews Happy Facepositive
Negative Reviews Sad Facenegative

Nov, 29, 2022

$COSM gastric bypass and bariatric surgery will ha... See more

TGTX

TG Therapeutics Inc

-19.05%

$18.43 - $14.92

Feb 7th 2023 - Mar 21st 2023

Positive Reviews Happy Facepositive
Negative Reviews Sad Facenegative

Mar, 21, 2023

$TGTX MOST CONVENIENT- 50% faster infusion SAFEST - Zero Breast Cancer Risk MOST AFFORDABLE - By far If TGTX was a Big Pharma Company, the medical press would be blowing it up with praise.

Mar, 13, 2023

INFUSION TIME 3.NO BREAST CANCER ISSUES 4.

Feb, 3, 2023

- Lowest ARR rate, no black box label, reduced brain lesions, and no reports of breast cancer.

Jan, 27, 2023

Lowest ARR rate, no black box warning label, reduced brain lesions, and no reports of breast cancer (there are reports of breast cancer with other MS treatments, and 75% of people with MS are women).

Jan, 16, 2023

$TGTX "4 Stories of Living with Multiple Sclerosis" Briumvi, the best and most affordable, 1HR infusion, no black box label warning, and no warning or report of causing breast cancer.

Jan, 12, 2023

No breast cancer risk.

Jan, 10, 2023

Major upgrade for patients and infusion centers -No major health threats like breast cancer or sever liver damage like main competition

Jan, 6, 2023

$TGTX possibly the best therapy available for MS patients that exists today!

Jan, 5, 2023

MS is 3 times more common in women and there were no reports of breast cancer compared to the competition!

SLS

SELLAS Life Sciences Group Inc

-63.99%

$3.61 - $1.30

Feb 7th 2023 - Mar 21st 2023

Positive Reviews Happy Facepositive
Negative Reviews Sad Facenegative

Mar, 20, 2023

These patients experienced about 35% longer survival than has been reported for other second-line therapies.

Mar, 20, 2023

* Best Available Therapy offers 6-8 months of Overall Survival * All pooled Regal patients, BAT and Gps combined, is 16 months.

Mar, 17, 2023

* Best Available Therapy offers 6-8 months of Overall Survival * All pooled Regal patients, BAT and Gps combined, is 16 months.

Mar, 17, 2023

* Best Available Therapy offers 6-8 months of Overall Survival * All pooled Regal patients, BAT and Gps combined, is 16 months.

Mar, 13, 2023

Good cancer stock from what I hear in 2028.

Feb, 6, 2023

$MRK Ovarian cancer data final P2 results are better than any other drugs by a mile.

Feb, 3, 2023

They address a broad range of cancer indications.

Feb, 3, 2023

$SLS Gps arm 22 months of median Overall Survival Best Available Therapy 8.

Feb, 1, 2023

$SLS In addition to GPs FDA approval for AML secondary Remission patients - Gps + Keytruda/Checkpoint Inhibition is also best in class for Ovarian cancer patients.

Jan, 24, 2023

The nation’s best means the O'Neal Comprehensive Center in Alabama have access to the latest therapies, cutting-edge clinical trials and the expertise needed to treat their cancer.

COSM

Cosmos Holdings Inc

-39.30%

$5.00 - $3.04

Feb 7th 2023 - Mar 21st 2023

Positive Reviews Happy Facepositive
Negative Reviews Sad Facenegative

Nov, 29, 2022

$COSM gastric bypass and bariatric surgery will have a new competitor in the Clinical Weight Loss realm, one that is much less risky, Cosmos Health new weight loss product will revolutionize weight loss as it is much less invasive.